Rituximab in Treating Patients With Hodgkin's Lymphoma
Trial ID or NCT#
Phase 2 trial to study the effectiveness of rituximab in treating patients who have lymphocyte-predominant Hodgkin's lymphoma.
Phase 2 Trial to Evaluate the Efficacy of Anti-CD20 Antibody in Patients With Lymphocyte Predominant Hodgkin's Disease
Contact us to find out if this trial is right for you.
About this Clinical Trial
Your Message Will Go ToSarah Daadi
Go Back To The Trial